Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Core Laboratories (CLB) EBT (2022 - 2025)

Core Laboratories' EBT history spans 4 years, with the latest figure at $13.2 million for Q4 2025.

  • For Q4 2025, EBT rose 14.53% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $45.9 million, down 0.53%, while the annual FY2025 figure was $45.9 million, 0.63% down from the prior year.
  • EBT reached $13.2 million in Q4 2025 per CLB's latest filing, down from $18.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $18.3 million in Q3 2025 to a low of $1.8 million in Q1 2025.
  • Average EBT over 4 years is $11.1 million, with a median of $11.5 million recorded in 2024.
  • Peak YoY movement for EBT: soared 75.18% in 2023, then plummeted 64.41% in 2025.
  • A 4-year view of EBT shows it stood at $12.5 million in 2022, then dropped by 12.55% to $11.0 million in 2023, then grew by 5.31% to $11.5 million in 2024, then grew by 14.53% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for CLB's EBT are $13.2 million (Q4 2025), $18.3 million (Q3 2025), and $12.6 million (Q2 2025).